- AdventHealth
AdventHealth for Children is partnering with Rady Children’s Institute for Genomic Medicine to bring rapid and ultra-rapid whole genome sequencing to Central Florida families for the first time. The testing will help critically ill babies and children in intensive care with unexplained medical conditions receive appropriate care.
This advanced diagnostic technology rapidly identifies the causes of rare genetic disorders in some of the sickest infants and children. AdventHealth selected Rady in order to bring the quickest turnaround of genomic test results available in the country to patients in Central Florida. Preliminary diagnoses are typically available in less than three days for medically urgent cases.
“Genomics is the future of medicine. This advanced testing can have a significant impact on how we diagnose and treat patients,” said Dr. Rajan Wadhawan, a board-certified neonatologist and senior executive officer of AdventHealth for Children and AdventHealth for Women. “Rady Children’s Institute is a leader in genomic medicine, and this partnership will help us provide the best care to some of the littlest and sickest patients in our care.”
“Our team is focused on using the power of rapid Whole Genome Sequencing to identify or rule out most genetic diseases in one swift step and empower the medical team at the bedside to provide personalized treatment and improve outcomes,” said Dr. Stephen Kingsmore, president and CEO of Rady Children’s Institute for Genomic Medicine. “We’re delighted to partner with AdventHealth to bring the life-changing benefits of Rapid Precision Medicine® to the children and families of Central Florida.”
Located on the campus of Rady Children’s Hospital in San Diego, the Rady Children’s Institute houses a state-of-the-art genome sequencing lab and employs a multi-disciplinary team of experts who specialize in providing timely and accurate guidance to physicians caring for children with rare genetic disease.
The Rady partnership is the latest in AdventHealth’s investment in genomics. In 2019, AdventHealth launched the “WholeMe” study, which is ongoing. Ten-thousand people have the opportunity to join WholeMe, in which AdventHealth’s partner Helix will evaluate their DNA for the genes linked to familial hypercholesterolemia, known as “FH.” FH is a life-threatening genetic condition that causes high cholesterol. If left untreated, it can lead to a heart attack, even in young adults.
AdventHealth is also welcoming Dr. Majed Dasouki, a leading expert on the field of genetic medicine. He will serve as the medical director for AdventHealth Medical Group’s genetic medicine practice in Orlando. In this role, he will help patients and families interpret genetic test results and develop treatment plans for those with genetic disorders, both children and adults. Dasouki previously served as the director of the Newborn Screening and Biochemical Genetics Laboratory (NSBGL) at King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia.
Contact: CFD External Communications
Tel: Call CFD External Communications at407-303-5950
Email: Email CFD External Communications atCFDExternalComm@adventhealth.com
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...